Annual net sale milestones in the Territory per license agreement.

No definition available.

Name:	txmd_AnnualNetSalesMilestone
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from license agreement.

+ References

No definition available.

+ Details

Name:	txmd_CashUpfrontPaymentReceived
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.

+ References

No definition available.

+ Details

Name:	txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payments upon FDA approval.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentUponFDAApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payments payable after release of first commercial batch.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The net sales amount as defined in license agreement for step-based royalty payments.

+ References

No definition available.

+ Details

Name:	txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of issued patents.

+ References

No definition available.

+ Details

Name:	txmd_NumberOfIssuedPatents
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.

+ References

No definition available.

+ Details

Name:	txmd_RegulatoryMilestoneAdditionalPayment
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The percent of the net sales to be paid as royalty per license agreement.

+ References

No definition available.

+ Details

Name:	txmd_RoyaltyPercent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of sales milestone payments per licensing agreement.

+ References

No definition available.

+ Details

Name:	txmd_SalesMilestonePaymentsInTranches
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of amortization of other deferred costs recognized in the income statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_OtherAmortizationOfDeferredCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentDLimoneneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

NOTE 7 – INTANGIBLE ASSETS (Details Narrative)			3 Months Ended		9 Months Ended
NOTE 7 – INTANGIBLE ASSETS (Details Narrative)	Aug. 05, 2019 EUR (€)	Aug. 06, 2018 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jun. 06, 2019 EUR (€)
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)					$ 78,864
Amortization of Intangible Assets			$ 51,259	$ 31,100	140,206	$ 77,123
Amortization of Other Deferred Charges					$ 15,998
Stock Issued During Period, Value, New Issues				$ 89,907,797
Subscription Agreement Knight [Member]
Finite-Lived Intangible Assets [Line Items]
Stock Issued During Period, Shares, New Issues \| shares		3,921,568
Sale of Stock, Price Per Share \| $ / shares		$ 5.10
Stock Issued During Period, Value, New Issues		$ 20,000,000
Council License Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent					5000.00%
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent					2000.00%
maximum costs and expenses for post approval					$ 20,000,000
Council License Agreement [Member] \| ANNOVERA [Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payment upon FDA Approval			20,000,000
Milestone payments (payment after release of first commercial batch)			20,000,000		20,000,000
Finite-lived Intangible Assets Acquired			20,000,000
Amortization of Other Deferred Charges			$ 15,998		15,998
Council License Agreement [Member] \| ANNOVERA [Member] \| Step-based Royalty Payment One [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty					$ 50,000,000
CouncilLicenseAgreementStep1Member
Finite-Lived Intangible Assets [Line Items]
Royalty (percent)					500.00%
CouncilLicenseAgreementStep2Member
Finite-Lived Intangible Assets [Line Items]
Royalty (percent)					1000.00%
CouncilLicenseAgreementStep2Member \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty					$ 150,000,000
CouncilLicenseAgreementStep2Member \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty					$ 50,000,000
CouncilLicenseAgreementStep3Member
Finite-Lived Intangible Assets [Line Items]
Royalty (percent)					1500.00%
CouncilLicenseAgreementStep3Member \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty					$ 150,000,000
License Agreement Theramex Member
Finite-Lived Intangible Assets [Line Items]
Cash upfront payment received \| €	€ 14,000,000
License Agreement Theramex Member \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Regulatory milestone payments \| €							€ 2,000,000
Sales milestone payment \| €							€ 27,500,000
Sales milestone \| €	100,000,000
License Agreement Theramex Member \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Sales milestone \| €	€ 25,000,000
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life					20 years
Domestic US Patents
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			26		26
Foreign Patents Member
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			28		28
Domestic Patents BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			12		12
Foreign Patents BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			6		6
Domestic Patents NonApproved BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			3		3
Domestic US Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			5		5
Domestic US Utility Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			4		4
Domestic US Design Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			1		1
Foreign Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			13		13
Foreign Utility Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			3		3
Foreign Design Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			10		10
Domestic US Patents Topical Cream
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			1		1
Domestic Utility Patent Transdermal Patch
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			1		1
Foreign Utility Patent Transdermal Patch
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			5		5
Domestic Utility Patent Opera
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			1		1
Domestic Utility Patent DLimonene
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			1		1
Domestic Utility Patent TX009HR
Finite-Lived Intangible Assets [Line Items]
Number of issued patents			2		2